Clinical Correlation Of A Precision Medicine Test With Treatment Outcome In Acute Myeloid Leukemia Patients

Introduction: Precision Medicine (PM) by measuring the pharmacological activity of drug combination treatments in patient samples by flow cytometry is a new field. This approach has been validated in an observational study of 236 Acute Myeloid Leukemia (AML) patients from Spain and China. Patients were treated with commonly administered chemotherapeutic regimens in AML, and the PM test generated a ranking of the activity of alternative treatments in each patient sample to support personalizing treatments in clinical practice.